Back to Search

A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

  • Protocol Number: 202211169
  • Principal Investigator: Anadkat, Milan
  • Cancer Types: Gastrointestinal, Lung

For more information on this trial, contact us here:

[email protected]

Brief Summary

Protocol Interventions